Setsuko Chambers

Grants(34)

Developing Personalized Ovarian Cancer Risk Prediction through Circulating miRNA Biomarkers in 'Non-Genetic High-Risk' Women
Active·2024·$125K / $250K·
External
Principal Investigator (PI)
ovarian cancer risk, circulating biomarkers, mirna, personalized prediction, high-risk women
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tu
Active·2023·$560.9K·
External
Principal Investigator (PI)
ovarian cancer, combination therapy, platinum-resistant, peritoneal cancer, fallopian-tube cancer
Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in Folate
Active·2023·$1.7M / $419.4K·
External
Principal Investigator (PI)
chemotherapy, antibody-drug conjugate, ovarian cancer, clinical trial, folate receptor
A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women
Active·2023·$270.2K·
External
Principal Investigator (PI)
clinical trials, cancer treatment, immunotherapy, chemotherapy, women's health
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without
Active·2021·$339.8K·
External
Principal Investigator (PI)
oncology, immunotherapy, clinical trial, chemotherapy, lung cancer

Page 1 of 7

People

Profile

Collaboration(33)

Hao Zhang

H-H. Sherry Chow

Cynthia Thomson

Denise Roe

Teshia Solomon

Grants(34)

Developing Personalized Ovarian Cancer Risk Prediction through Circulating miRNA Biomarkers in 'Non-Genetic High-Risk' Women

A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tu

Multicenter, Open-label, Phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in Folate

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without

Publications(79)

Antiandrogen Flutamide-Induced Restoration of miR-449 Expression Mitigates Molecular Markers Associated with Ovarian Cancer Risk

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study

Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution

A Phase III Study of Pafolacianine Injection OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer Study 006)

Advances in Chemotherapy and Targeted Therapies in Endometrial Cancer

NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8

A Randomized Phase 3 Study of Pafolacianine Injection OTL38) for Intraoperative Imaging of Folate Receptor Positive Ovarian Cancer

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 Parts 1 and 2)

Frequency and Characteristics of Large Deletion Carriers in Patients with Muir-Torre Syndrome